The company’s brain-computer interface is implanted in a blood vessel on the brain’s surface and is designed to restore the capability for severely paralyzed patients to control devices with hands-free point-and-click, according to a Dec. 15 Synchron news release.
The financing will be used to launch a clinical trial.
ARCH Venture Partners led the financing, bringing Synchron’s total capital raised to $145 million.
